Highlights from: The 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology
暂无分享,去创建一个
R. Herbst | D. Gandara | P. Lara | M. Shrader | A. Ranganathan | David J. Lee | S. Muneer | Aarati Ranganathan
[1] Lesley Seymour,et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Sabine Tejpar,et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience , 2008 .
[3] R. Ramlau,et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) , 2008 .
[4] D. Kerr,et al. VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION , 2008 .
[5] C. Bokemeyer,et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience , 2008 .
[6] R. Herbst,et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Zucali. Signal Transduction Inhibitors, HER Family, EGFR Inhibition and Clinical Achievements , 2007 .
[8] T. Lynch,et al. B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC) , 2007 .
[9] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[10] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[11] Edward S. Kim,et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[13] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[14] G. Fontanini,et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] N. Goldstein,et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.